Assignee
TIGENIX S A U
ES·9 granted patents·11 pending applications·12 citations·filing 2014–2022
Top patents by PatentIndex Score
20 records- 0183US9943550B2Cell populations having immunoregulatory activity, method for isolation and usesTIGENIX S A U·Filed 2014·Granted Apr 17, 2018·8 cites·8 claims
- 0275US12186344B2Cell populations having immunoregulatory activity, method for isolation and usesTIGENIX S A U·Filed 2022·Granted Jan 7, 2025·0 cites·13 claims
- 0375US10357518B2Adipose tissue-derived stromal stem cells for use in treating refractory complex perianal fistulas in Crohn's diseaseTIGENIX S A U·Filed 2017·Granted Jul 23, 2019·2 cites·20 claims
- 0474US2020206274A1Use of adipose tissue-derived stromal stem cells in treating fistulaTIGENIX S A U·Filed 2019·Application pending·0 cites
- 0572US10758575B2Use of adipose tissue-derived stromal stem cells in treating fistulaTIGENIX S A U·Filed 2014·Granted Sep 1, 2020·0 cites·22 claims
- 0671US10729726B2Identification and isolation of multipotent cells from non-osteochondral mesenchymal tissueTIGENIX S A U·Filed 2015·Granted Aug 4, 2020·1 cites·4 claims
- 0767US10780132B2Use of adipose tissue-derived stromal stem cells in treating fistulaTIGENIX S A U·Filed 2017·Granted Sep 22, 2020·0 cites·4 claims
- 0867US10660920B2Lymphocyte biomarkers for determining the clinical response to cell therapyTIGENIX S A U·Filed 2014·Granted May 26, 2020·1 cites·16 claims
- 0961US11478511B2Lymphocyte biomarkers for determining the clinical response to cell therapyTIGENIX S A U·Filed 2020·Granted Oct 25, 2022·0 cites·16 claims
- 1057US11253632B2Biomaterial for suturingTIGENIX S A U·Filed 2019·Granted Feb 22, 2022·0 cites·6 claims
- 1154US2017296592A1Cell populations having immunoregulatory activity, method for isolation and usesTIGENIX S A U·Filed 2017·Application pending·0 cites
- 1254US2017296593A1Cell populations having immunoregulatory activity, method for isolation and usesTIGENIX S A U·Filed 2017·Application pending·0 cites
- 1354US2020376038A1Mesenchymal stromal cells for treating sepsisTIGENIX S A U·Filed 2020·Application pending·0 cites
- 1440US2016120910A1Cell populations having immunoregulatory activity, methods for the preparation and uses thereofTIGENIX S A U·Filed 2014·Application pending·0 cites
- 1536US2022104481A1Cryopreservation of stem cellsTIGENIX S A U·Filed 2020·Application pending·0 cites
- 1635US2017151284A1Mesenchymal stromal cells for treating sepsisTIGENIX S A U·Filed 2015·Application pending·0 cites
- 1732US2017119682A1Mesenchymal stem cell-derived exosomes and their usesTIGENIX S A U·Filed 2016·Application pending·0 cites
- 1831US2022202868A1Improved stem cell populations for allogeneic therapyTIGENIX S A U·Filed 2020·Application pending·0 cites
- 1928US2017136065A1Mesenchymal stromal cells for treating rheumatoid arthritisTIGENIX S A U·Filed 2015·Application pending·0 cites
- 2024US2017121685A1Mesenchymal stem cell-derived exosomes and their usesTIGENIX S A U·Filed 2015·Application pending·0 cites
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →